Selected research
Industry Research
OX40 Receptor Agonist Industry Research Report 2026
Market perspective
The global OX40 Receptor Agonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for OX40 Receptor Agonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for OX40 Receptor Agonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of OX40 Receptor Agonist include Roche, Pfizer, GlaxoSmithKline, Sorrento Therapeutics, Merk, Incyte, Glenmark, Bristol Myers Squibb and Bioinvent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global OX40 Receptor Agonist market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
OX40 Receptor Agonist Market by Company
Roche
Pfizer
GlaxoSmithKline
Sorrento Therapeutics
Merk
Incyte
Glenmark
Bristol Myers Squibb
Bioinvent
AstraZeneca (MedImmune)
Agenus
OX40 Receptor Agonist Segment by Type
Fully Human IgG1 Agonist mAb
Fully Human IgG2 Agonist Ab
Humanised IgG1 Agonist mAb
OX40 Receptor Agonist Segment by Application
Myasthenia Gravis
Psoriasis
Cancers
OX40 Receptor Agonist Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OX40 Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of OX40 Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OX40 Receptor Agonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of OX40 Receptor Agonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of OX40 Receptor Agonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of OX40 Receptor Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fully Human IgG1 Agonist mAb
- Fully Human IgG2 Agonist Ab
- Humanised IgG1 Agonist mAb
Applications
- Myasthenia Gravis
- Psoriasis
- Cancers
Companies covered
- Roche
- Pfizer
- GlaxoSmithKline
- Sorrento Therapeutics
- Merk
- Incyte
- Glenmark
- Bristol Myers Squibb
- Bioinvent
- AstraZeneca (MedImmune)
- Agenus
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global OX40 Receptor Agonist Market Size (2021-2032)
- 2.2.2 Global OX40 Receptor Agonist Sales (2021-2032)
- 2.2.3 Global OX40 Receptor Agonist Market Average Price (2021-2032)
- 2.3 OX40 Receptor Agonist by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Fully Human IgG1 Agonist mAb
- 2.3.3 Fully Human IgG2 Agonist Ab
- 2.3.4 Humanised IgG1 Agonist mAb
- 2.4 OX40 Receptor Agonist by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Myasthenia Gravis
- 2.4.3 Psoriasis
- 2.4.4 Cancers
3 Market Competitive Landscape by Manufacturers
- 3.1 Global OX40 Receptor Agonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global OX40 Receptor Agonist Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global OX40 Receptor Agonist Revenue of Manufacturers (2021-2026)
- 3.4 Global OX40 Receptor Agonist Average Price by Manufacturers (2021-2026)
- 3.5 Global OX40 Receptor Agonist Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of OX40 Receptor Agonist, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of OX40 Receptor Agonist, Product Type & Application
- 3.8 Global Manufacturers of OX40 Receptor Agonist, Established Date
- 3.9 Global OX40 Receptor Agonist Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Roche
- 4.1.1 Roche Company Information
- 4.1.2 Roche Business Overview
- 4.1.3 Roche OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Roche OX40 Receptor Agonist Product Portfolio
- 4.1.5 Roche Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer OX40 Receptor Agonist Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 GlaxoSmithKline
- 4.3.1 GlaxoSmithKline Company Information
- 4.3.2 GlaxoSmithKline Business Overview
- 4.3.3 GlaxoSmithKline OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline OX40 Receptor Agonist Product Portfolio
- 4.3.5 GlaxoSmithKline Recent Developments
- 4.4 Sorrento Therapeutics
- 4.4.1 Sorrento Therapeutics Company Information
- 4.4.2 Sorrento Therapeutics Business Overview
- 4.4.3 Sorrento Therapeutics OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio
- 4.4.5 Sorrento Therapeutics Recent Developments
- 4.5 Merk
- 4.5.1 Merk Company Information
- 4.5.2 Merk Business Overview
- 4.5.3 Merk OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merk OX40 Receptor Agonist Product Portfolio
- 4.5.5 Merk Recent Developments
- 4.6 Incyte
- 4.6.1 Incyte Company Information
- 4.6.2 Incyte Business Overview
- 4.6.3 Incyte OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Incyte OX40 Receptor Agonist Product Portfolio
- 4.6.5 Incyte Recent Developments
- 4.7 Glenmark
- 4.7.1 Glenmark Company Information
- 4.7.2 Glenmark Business Overview
- 4.7.3 Glenmark OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Glenmark OX40 Receptor Agonist Product Portfolio
- 4.7.5 Glenmark Recent Developments
- 4.8 Bristol Myers Squibb
- 4.8.1 Bristol Myers Squibb Company Information
- 4.8.2 Bristol Myers Squibb Business Overview
- 4.8.3 Bristol Myers Squibb OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio
- 4.8.5 Bristol Myers Squibb Recent Developments
- 4.9 Bioinvent
- 4.9.1 Bioinvent Company Information
- 4.9.2 Bioinvent Business Overview
- 4.9.3 Bioinvent OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bioinvent OX40 Receptor Agonist Product Portfolio
- 4.9.5 Bioinvent Recent Developments
- 4.10 AstraZeneca (MedImmune)
- 4.10.1 AstraZeneca (MedImmune) Company Information
- 4.10.2 AstraZeneca (MedImmune) Business Overview
- 4.10.3 AstraZeneca (MedImmune) OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio
- 4.10.5 AstraZeneca (MedImmune) Recent Developments
- 4.11 Agenus
- 4.11.1 Agenus Company Information
- 4.11.2 Agenus Business Overview
- 4.11.3 Agenus OX40 Receptor Agonist Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Agenus OX40 Receptor Agonist Product Portfolio
- 4.11.5 Agenus Recent Developments
5 Global OX40 Receptor Agonist Market Scenario by Region
- 5.1 Global OX40 Receptor Agonist Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global OX40 Receptor Agonist Sales by Region: 2021-2032
- 5.2.1 Global OX40 Receptor Agonist Sales by Region: 2021-2026
- 5.2.2 Global OX40 Receptor Agonist Sales by Region: 2027-2032
- 5.3 Global OX40 Receptor Agonist Revenue by Region: 2021-2032
- 5.3.1 Global OX40 Receptor Agonist Revenue by Region: 2021-2026
- 5.3.2 Global OX40 Receptor Agonist Revenue by Region: 2027-2032
- 5.4 North America OX40 Receptor Agonist Market Facts & Figures by Country
- 5.4.1 North America OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America OX40 Receptor Agonist Sales by Country (2021-2032)
- 5.4.3 North America OX40 Receptor Agonist Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe OX40 Receptor Agonist Market Facts & Figures by Country
- 5.5.1 Europe OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe OX40 Receptor Agonist Sales by Country (2021-2032)
- 5.5.3 Europe OX40 Receptor Agonist Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific OX40 Receptor Agonist Market Facts & Figures by Country
- 5.6.1 Asia Pacific OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific OX40 Receptor Agonist Sales by Country (2021-2032)
- 5.6.3 Asia Pacific OX40 Receptor Agonist Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America OX40 Receptor Agonist Market Facts & Figures by Country
- 5.7.1 South America OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America OX40 Receptor Agonist Sales by Country (2021-2032)
- 5.7.3 South America OX40 Receptor Agonist Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa OX40 Receptor Agonist Market Facts & Figures by Country
- 5.8.1 Middle East and Africa OX40 Receptor Agonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa OX40 Receptor Agonist Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa OX40 Receptor Agonist Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global OX40 Receptor Agonist Sales by Type (2021-2032)
- 6.1.1 Global OX40 Receptor Agonist Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global OX40 Receptor Agonist Sales Market Share by Type (2021-2032)
- 6.2 Global OX40 Receptor Agonist Revenue by Type (2021-2032)
- 6.2.1 Global OX40 Receptor Agonist Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global OX40 Receptor Agonist Revenue Market Share by Type (2021-2032)
- 6.3 Global OX40 Receptor Agonist Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global OX40 Receptor Agonist Sales by Application (2021-2032)
- 7.1.1 Global OX40 Receptor Agonist Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global OX40 Receptor Agonist Sales Market Share by Application (2021-2032)
- 7.2 Global OX40 Receptor Agonist Revenue by Application (2021-2032)
- 7.2.1 Global OX40 Receptor Agonist Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global OX40 Receptor Agonist Revenue Market Share by Application (2021-2032)
- 7.3 Global OX40 Receptor Agonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 OX40 Receptor Agonist Value Chain Analysis
- 8.1.1 OX40 Receptor Agonist Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 OX40 Receptor Agonist Production Mode & Process
- 8.2 OX40 Receptor Agonist Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 OX40 Receptor Agonist Distributors
- 8.2.3 OX40 Receptor Agonist Customers
9 Global OX40 Receptor Agonist Analyzing Market Dynamics
- 9.1 OX40 Receptor Agonist Industry Trends
- 9.2 OX40 Receptor Agonist Industry Drivers
- 9.3 OX40 Receptor Agonist Industry Opportunities and Challenges
- 9.4 OX40 Receptor Agonist Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst